Physician profile
Christie E Matter
NPI 1598745465
$15,478.12
in general payments reported to CMS, 2019-2025
41 companies · $3,217 in 2025
The $3,217 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,882 · 2021: $2,093 · 2022: $1,609 · 2023: $1,974 · 2024: $2,451 · 2025: $3,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,390 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.00 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,259.40 | 2019-2025 | Siliq, Jublia, Arazlo |
| Abbvie INC. | $2,573.30 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,372.58 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $931.64 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $920.69 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $868.14 | 2019-2025 | |
| Leo Pharma INC. | $851.55 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Amgen INC. | $722.89 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $563.18 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Pfizer INC. | $352.32 | 2019-2025 | |
| Lilly USA, LLC | $321.78 | 2019-2025 | Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $321.01 | 2019-2025 | |
| Organon LLC | $310.99 | 2025 | Vtama |
| Ucb, INC. | $276.96 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $220.34 | 2019-2025 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Matter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.